As a registered dietitian, I work with a lot of patients who are taking GLP-1 medications like semaglutide or tirzepatide.

You’re scrolling through your social media feed and notice a friend looks much thinner than they did a few months ago. Your coworker mentions she’s just “not hungry anymore.” Your group chat is ...

Most people first heard about GLP-1 drugs because a friend, a celebrity, or a headline mentioned dramatic weight loss. That's fair, since visible results tend to get attention. But the story happening ...

For veterans with type 2 diabetes (T2D) receiving basal insulin therapy, the addition of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) does not increase the rate of insulin discontinuation ...

Fractyl Health’s Revita targets the duodenal mucosa in an endoscopic ablation procedure. [Illustration courtesy of Fractyl Health] Fractyl Health (NASDAQ: GUTS) reported randomized clinical trial ...

1. The FDA approved orforglipron (Foundayo) on April 1, 2026, making it the first non-peptide oral GLP-1 receptor agonist cleared for obesity treatment and the first oral GLP-1 pill with no food or ...

In a target emulation trial of veterans on insulin for type 2 diabetes, those adding a GLP-1 agonist did not have higher basal insulin discontinuation rates compared with those starting another ...

Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech ...

GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published in the Journal ...

China will add a second GLP-1 drug, used to treat ‌diabetes, to a list of essential drugs all public hospitals are required to prioritise having in their formulary, a government statement said on ...

Phase 3 trials of Kailera Therapeutics’ oral GLP-1 prospect have hit their primary endpoints, positioning the biotech’s partner Hengrui Pharma to seek approval in obesity and diabetes in China.

Higher rates of reinitiation seen for Black or African American patients, those with ≥5 percent weight gain. (HealthDay News) — More than half of adults with type 2 diabetes mellitus (T2DM) who ...